Bank of New York Mellon Corp Sells 206,050 Shares of LivaNova PLC $LIVN

Bank of New York Mellon Corp trimmed its position in shares of LivaNova PLC (NASDAQ:LIVN) by 34.3% during the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 394,391 shares of the company’s stock after selling 206,050 shares during the quarter. Bank of New York Mellon Corp’s holdings in LivaNova were worth $25,067,000 at the end of the most recent reporting period.

A number of other large investors also recently modified their holdings of the company. UMB Bank n.a. grew its position in LivaNova by 22.6% in the 4th quarter. UMB Bank n.a. now owns 971 shares of the company’s stock valued at $60,000 after purchasing an additional 179 shares during the period. State of Michigan Retirement System increased its stake in LivaNova by 1.5% during the 1st quarter. State of Michigan Retirement System now owns 13,111 shares of the company’s stock valued at $833,000 after purchasing an additional 200 shares in the last quarter. Hantz Financial Services Inc. raised its holdings in LivaNova by 159.9% during the fourth quarter. Hantz Financial Services Inc. now owns 434 shares of the company’s stock worth $27,000 after buying an additional 267 shares during the last quarter. Parallel Advisors LLC raised its holdings in LivaNova by 28.8% during the fourth quarter. Parallel Advisors LLC now owns 1,266 shares of the company’s stock worth $78,000 after buying an additional 283 shares during the last quarter. Finally, Oregon Public Employees Retirement Fund lifted its stake in shares of LivaNova by 2.7% in the first quarter. Oregon Public Employees Retirement Fund now owns 11,250 shares of the company’s stock valued at $715,000 after buying an additional 300 shares in the last quarter. 97.64% of the stock is currently owned by institutional investors.

Insider Transactions at LivaNova

In other LivaNova news, Director Francesco Bianchi sold 1,800 shares of the stock in a transaction dated Tuesday, May 26th. The shares were sold at an average price of $75.75, for a total value of $136,350.00. Following the completion of the sale, the director owned 7,228 shares in the company, valued at approximately $547,521. This trade represents a 19.94% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Insiders own 0.35% of the company’s stock.

Analyst Ratings Changes

LIVN has been the subject of a number of analyst reports. KeyCorp lifted their price objective on shares of LivaNova from $83.00 to $92.00 and gave the company an “overweight” rating in a report on Monday, June 22nd. Freedom Capital upgraded shares of LivaNova to a “hold” rating in a report on Tuesday, June 30th. Mizuho raised their price target on shares of LivaNova from $90.00 to $95.00 and gave the company an “outperform” rating in a research report on Wednesday, July 15th. Weiss Ratings raised shares of LivaNova from a “sell (d+)” rating to a “hold (c)” rating in a research report on Thursday, May 7th. Finally, Robert W. Baird cut their price target on LivaNova from $78.00 to $76.00 and set an “outperform” rating for the company in a research note on Thursday, May 7th. One research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and four have given a Hold rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $81.38.

LivaNova Stock Performance

NASDAQ LIVN opened at $80.58 on Tuesday. LivaNova PLC has a 1 year low of $41.01 and a 1 year high of $85.27. The company has a debt-to-equity ratio of 0.24, a current ratio of 1.33 and a quick ratio of 1.11. The firm has a market cap of $4.43 billion, a price-to-earnings ratio of 41.32 and a beta of 0.86. The company has a fifty day moving average price of $78.47 and a 200-day moving average price of $69.70.

LivaNova (NASDAQ:LIVN) last released its quarterly earnings results on Wednesday, May 6th. The company reported $0.98 earnings per share for the quarter, beating analysts’ consensus estimates of $0.85 by $0.13. LivaNova had a net margin of 7.48% and a return on equity of 16.48%. The company had revenue of $362.26 million for the quarter, compared to analyst estimates of $346.05 million. During the same period last year, the firm earned $0.88 earnings per share. The firm’s revenue was up 14.3% on a year-over-year basis. LivaNova has set its FY 2026 guidance at 4.200-4.300 EPS. As a group, equities research analysts predict that LivaNova PLC will post 3.73 EPS for the current fiscal year.

LivaNova Profile

LivaNova plc is a global medical technology company that develops and manufactures products and therapies for the cardiac surgery and neuromodulation markets. Headquartered in London, United Kingdom, and Houston, Texas, LivaNova serves hospitals, clinics and healthcare providers in more than 100 countries. The company’s primary focus lies in advancing patient care through innovations in heart–lung bypass, cardiac preservation, circulatory support and neurostimulation therapies.

The Cardiac Surgery business unit offers a comprehensive portfolio of products used in cardiopulmonary bypass procedures, including oxygenators, heart–lung machines, arterial filters, cannulae and sutureless heart valves.